<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00855010</url>
  </required_header>
  <id_info>
    <org_study_id>112008-047</org_study_id>
    <secondary_id>1K23RRO24470-01</secondary_id>
    <nct_id>NCT00855010</nct_id>
    <nct_alias>NCT00896116</nct_alias>
  </id_info>
  <brief_title>Pioglitazone on Pancreatic Steatosis and Bone Health</brief_title>
  <official_title>Effect of Pioglitazone on Pancreatic Steatosis and Bone Health</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Texas Southwestern Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Institutes of Health (NIH)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Texas Southwestern Medical Center</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Randomized, double blind, placebo controlled trial evaluating the effect of pioglitazone on
      pancreatic fat content and bone turnover markers.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>February 2009</start_date>
  <completion_date type="Actual">December 2013</completion_date>
  <primary_completion_date type="Actual">December 2013</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Pancreatic Fat Content</measure>
    <time_frame>12 months</time_frame>
    <description>Pancreatic fat content was determined by proton magnetic resonance spectroscopy (1H-MRS) using a 1.5 Tesla Philips Intera system.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Bone Turnover Marker - Intact Parathyroid Hormone (PTH)</measure>
    <time_frame>12 months</time_frame>
    <description>Intact parathyroid hormone (PTH) were measured using enzyme-linked immunosorbent assay. .</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Bone Turnover Marker - Plasma 25-hydroxyvitamin D</measure>
    <time_frame>12 months</time_frame>
    <description>Plasma 25-hydroxyvitamin D was determined by radioimmunoassay</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Beta-cell Function</measure>
    <time_frame>12 months</time_frame>
    <description>Changes in B-cell function as measured by acute insulin release to glucose (AIRg)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Hepatic Fat Content</measure>
    <time_frame>12 months</time_frame>
    <description>Hepatic fat content was determined by proton magnetic resonance spectroscopy (1H-MRS) using a 1.5 Tesla Philips Intera system.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Subcutaneous Fat Area</measure>
    <time_frame>12 months</time_frame>
    <description>Abdominal MRI was performed to quantify subcutaneous fat area at the L2-L3 level.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Visceral Fat Area</measure>
    <time_frame>12 months</time_frame>
    <description>Abdominal MRI was performed to quantify visceral fat area at the L2-L3 level.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Bone Mineral Density</measure>
    <time_frame>12 months</time_frame>
    <description>Areal Bone Mineral Density at the L2-L4 antero-posterior lumbar spine, left femoral neck and total hip were measured by DXA scan using a Hologic Discovery Instrument scanner.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Disposition Index</measure>
    <time_frame>12 months</time_frame>
    <description>Disposition index is a measure of insulin secretion multiplied by insulin sensitivity, both derived from intravenous glucose tolerance test. A higher number means the pancreas is better able to lower blood glucose and a lower number means the pancreas is less able to lower blood glucose</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">42</enrollment>
  <condition>Obesity</condition>
  <condition>Type 2 Diabetes</condition>
  <arm_group>
    <arm_group_label>pioglitazone</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>pioglitazone tablet 45 mg once daily</description>
  </arm_group>
  <arm_group>
    <arm_group_label>placebo pill</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>placebo pill once daily (look-alike pill which contains no active ingredients)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>pioglitazone</intervention_name>
    <description>pioglitazone 45 mg daily</description>
    <arm_group_label>pioglitazone</arm_group_label>
    <other_name>Actos</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>placebo</intervention_name>
    <description>one daily</description>
    <arm_group_label>placebo pill</arm_group_label>
    <other_name>Placebo tablet resembling pioglitazone 45 mg.</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Fat level in the pancreas above 4% (measurement done by us with an MRI)

          -  English speaker

          -  over 21 years old

        Exclusion Criteria:

          -  contraindication to MRI

          -  anemia

          -  pregnancy or desire to conceive

          -  use of unapproved medications

          -  prior pancreatic disease

          -  use of more then 2 alcoholic drinks every day
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>21 Years</minimum_age>
    <maximum_age>99 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>UT Southwestern Medical Center</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75390</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>November 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 27, 2009</study_first_submitted>
  <study_first_submitted_qc>March 2, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 3, 2009</study_first_posted>
  <results_first_submitted>August 1, 2017</results_first_submitted>
  <results_first_submitted_qc>November 14, 2017</results_first_submitted_qc>
  <results_first_posted type="Actual">December 13, 2017</results_first_posted>
  <last_update_submitted>November 14, 2017</last_update_submitted>
  <last_update_submitted_qc>November 14, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">December 13, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Texas Southwestern Medical Center</investigator_affiliation>
    <investigator_full_name>Ildiko Lingvay</investigator_full_name>
    <investigator_title>MD, MPH, MSCS</investigator_title>
  </responsible_party>
  <keyword>Pioglitazone</keyword>
  <keyword>prediabetes</keyword>
  <keyword>diabetes</keyword>
  <keyword>obesity</keyword>
  <keyword>Pancreatic fat</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pioglitazone</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Pioglitazone</title>
          <description>pioglitazone tablet 45 mg once daily
pioglitazone: pioglitazone 45 mg daily: 23 subjects</description>
        </group>
        <group group_id="P2">
          <title>Placebo Pill</title>
          <description>placebo pill once daily (look-alike pill which contains no active ingredients)
placebo: one daily: 19 subjects</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="23"/>
                <participants group_id="P2" count="19"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="19"/>
                <participants group_id="P2" count="18"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Pioglitazone</title>
          <description>pioglitazone tablet 45 mg once daily
pioglitazone: pioglitazone 45 mg daily: 23</description>
        </group>
        <group group_id="B2">
          <title>Placebo Pill</title>
          <description>placebo pill once daily (look-alike pill which contains no active ingredients)
placebo: one daily: 19</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="23"/>
            <count group_id="B2" value="19"/>
            <count group_id="B3" value="42"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="22"/>
                    <measurement group_id="B2" value="18"/>
                    <measurement group_id="B3" value="40"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="52.6" spread="9.9"/>
                    <measurement group_id="B2" value="52.2" spread="10.6"/>
                    <measurement group_id="B3" value="52.4" spread="10.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="11"/>
                    <measurement group_id="B2" value="16"/>
                    <measurement group_id="B3" value="27"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="12"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="23"/>
                    <measurement group_id="B2" value="19"/>
                    <measurement group_id="B3" value="42"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Pancreatic Fat Content</title>
        <description>Pancreatic fat content was determined by proton magnetic resonance spectroscopy (1H-MRS) using a 1.5 Tesla Philips Intera system.</description>
        <time_frame>12 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Pioglitazone</title>
            <description>pioglitazone tablet 45 mg once daily
pioglitazone: pioglitazone 45 mg daily: 23 subjects</description>
          </group>
          <group group_id="O2">
            <title>Placebo Pill</title>
            <description>placebo pill once daily (look-alike pill which contains no active ingredients)
placebo: one daily: 19 subjects</description>
          </group>
        </group_list>
        <measure>
          <title>Pancreatic Fat Content</title>
          <description>Pancreatic fat content was determined by proton magnetic resonance spectroscopy (1H-MRS) using a 1.5 Tesla Philips Intera system.</description>
          <units>Percentage of fat</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="23"/>
                <count group_id="O2" value="19"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9.6" lower_limit="5.1" upper_limit="16.6"/>
                    <measurement group_id="O2" value="13.0" lower_limit="6.1" upper_limit="20.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Bone Turnover Marker - Intact Parathyroid Hormone (PTH)</title>
        <description>Intact parathyroid hormone (PTH) were measured using enzyme-linked immunosorbent assay. .</description>
        <time_frame>12 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Pioglitazone:</title>
            <description>pioglitazone tablet 45 mg once daily
pioglitazone: pioglitazone 45 mg daily</description>
          </group>
          <group group_id="O2">
            <title>Placebo Pill:</title>
            <description>placebo pill once daily (look-alike pill which contains no active ingredients)
placebo: one daily</description>
          </group>
        </group_list>
        <measure>
          <title>Bone Turnover Marker - Intact Parathyroid Hormone (PTH)</title>
          <description>Intact parathyroid hormone (PTH) were measured using enzyme-linked immunosorbent assay. .</description>
          <units>pg/mL</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="23"/>
                <count group_id="O2" value="19"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="41" lower_limit="38" upper_limit="57"/>
                    <measurement group_id="O2" value="56" lower_limit="51" upper_limit="74"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Bone Turnover Marker - Plasma 25-hydroxyvitamin D</title>
        <description>Plasma 25-hydroxyvitamin D was determined by radioimmunoassay</description>
        <time_frame>12 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Pioglitazone</title>
            <description>pioglitazone tablet 45 mg once daily
pioglitazone: pioglitazone 45 mg daily: 23 subjects</description>
          </group>
          <group group_id="O2">
            <title>Placebo Pill</title>
            <description>placebo pill once daily (look-alike pill which contains no active ingredients)
placebo: one daily: 19 subjects</description>
          </group>
        </group_list>
        <measure>
          <title>Bone Turnover Marker - Plasma 25-hydroxyvitamin D</title>
          <description>Plasma 25-hydroxyvitamin D was determined by radioimmunoassay</description>
          <units>ng/mL</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="23"/>
                <count group_id="O2" value="19"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="25" lower_limit="15" upper_limit="30"/>
                    <measurement group_id="O2" value="19" lower_limit="14" upper_limit="25"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Beta-cell Function</title>
        <description>Changes in B-cell function as measured by acute insulin release to glucose (AIRg)</description>
        <time_frame>12 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Pioglitazone</title>
            <description>pioglitazone tablet 45 mg once daily
pioglitazone: pioglitazone 45 mg daily</description>
          </group>
          <group group_id="O2">
            <title>Placebo Pill</title>
            <description>placebo pill once daily (look-alike pill which contains no active ingredients)
placebo: one daily</description>
          </group>
        </group_list>
        <measure>
          <title>Beta-cell Function</title>
          <description>Changes in B-cell function as measured by acute insulin release to glucose (AIRg)</description>
          <units>microUnits/mL x min</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="23"/>
                <count group_id="O2" value="19"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="101" lower_limit="40" upper_limit="352"/>
                    <measurement group_id="O2" value="494" lower_limit="264" upper_limit="748"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Hepatic Fat Content</title>
        <description>Hepatic fat content was determined by proton magnetic resonance spectroscopy (1H-MRS) using a 1.5 Tesla Philips Intera system.</description>
        <time_frame>12 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Pioglitazone</title>
            <description>pioglitazone tablet 45 mg once daily
pioglitazone: pioglitazone 45 mg daily: 23 subjects</description>
          </group>
          <group group_id="O2">
            <title>Placebo Pill</title>
            <description>placebo pill once daily (look-alike pill which contains no active ingredients)
placebo: one daily: 19 subjects</description>
          </group>
        </group_list>
        <measure>
          <title>Hepatic Fat Content</title>
          <description>Hepatic fat content was determined by proton magnetic resonance spectroscopy (1H-MRS) using a 1.5 Tesla Philips Intera system.</description>
          <units>percentage</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="23"/>
                <count group_id="O2" value="19"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.0" lower_limit="1.7" upper_limit="10.9"/>
                    <measurement group_id="O2" value="5.8" lower_limit="3.6" upper_limit="16.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Subcutaneous Fat Area</title>
        <description>Abdominal MRI was performed to quantify subcutaneous fat area at the L2-L3 level.</description>
        <time_frame>12 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Pioglitazone</title>
            <description>pioglitazone tablet 45 mg once daily
pioglitazone: pioglitazone 45 mg daily: 23 subjects</description>
          </group>
          <group group_id="O2">
            <title>Placebo Pill</title>
            <description>placebo pill once daily (look-alike pill which contains no active ingredients)
placebo: one daily: 19 subjects</description>
          </group>
        </group_list>
        <measure>
          <title>Subcutaneous Fat Area</title>
          <description>Abdominal MRI was performed to quantify subcutaneous fat area at the L2-L3 level.</description>
          <units>cm^2</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="23"/>
                <count group_id="O2" value="19"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="243" spread="133"/>
                    <measurement group_id="O2" value="378" spread="179"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Visceral Fat Area</title>
        <description>Abdominal MRI was performed to quantify visceral fat area at the L2-L3 level.</description>
        <time_frame>12 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Pioglitazone</title>
            <description>pioglitazone tablet 45 mg once daily
pioglitazone: pioglitazone 45 mg daily: 23 subjects</description>
          </group>
          <group group_id="O2">
            <title>Placebo Pill</title>
            <description>placebo pill once daily (look-alike pill which contains no active ingredients)
placebo: one daily: 19 subjects</description>
          </group>
        </group_list>
        <measure>
          <title>Visceral Fat Area</title>
          <description>Abdominal MRI was performed to quantify visceral fat area at the L2-L3 level.</description>
          <units>cm^2</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="23"/>
                <count group_id="O2" value="19"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="302" spread="88"/>
                    <measurement group_id="O2" value="273" spread="89"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Bone Mineral Density</title>
        <description>Areal Bone Mineral Density at the L2-L4 antero-posterior lumbar spine, left femoral neck and total hip were measured by DXA scan using a Hologic Discovery Instrument scanner.</description>
        <time_frame>12 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Pioglitazone</title>
            <description>pioglitazone tablet 45 mg once daily
pioglitazone: pioglitazone 45 mg daily: 23 subjects</description>
          </group>
          <group group_id="O2">
            <title>Placebo Pill</title>
            <description>placebo pill once daily (look-alike pill which contains no active ingredients)
placebo: one daily: 19 subjects</description>
          </group>
        </group_list>
        <measure>
          <title>Bone Mineral Density</title>
          <description>Areal Bone Mineral Density at the L2-L4 antero-posterior lumbar spine, left femoral neck and total hip were measured by DXA scan using a Hologic Discovery Instrument scanner.</description>
          <units>g/cm^2</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="23"/>
                <count group_id="O2" value="19"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>L2-L4 Lumbar spine BMD</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.03" spread="0.14"/>
                    <measurement group_id="O2" value="1.03" spread="0.14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Left femoral neck</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.83" spread="0.09"/>
                    <measurement group_id="O2" value="0.85" spread="0.13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Left total hip</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.96" spread="0.12"/>
                    <measurement group_id="O2" value="1.02" spread="0.12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Disposition Index</title>
        <description>Disposition index is a measure of insulin secretion multiplied by insulin sensitivity, both derived from intravenous glucose tolerance test. A higher number means the pancreas is better able to lower blood glucose and a lower number means the pancreas is less able to lower blood glucose</description>
        <time_frame>12 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Pioglitazone:</title>
            <description>pioglitazone tablet 45 mg once daily
pioglitazone: pioglitazone 45 mg daily</description>
          </group>
          <group group_id="O2">
            <title>Placebo Pill:</title>
            <description>placebo pill once daily (look-alike pill which contains no active ingredients)
placebo: one daily</description>
          </group>
        </group_list>
        <measure>
          <title>Disposition Index</title>
          <description>Disposition index is a measure of insulin secretion multiplied by insulin sensitivity, both derived from intravenous glucose tolerance test. A higher number means the pancreas is better able to lower blood glucose and a lower number means the pancreas is less able to lower blood glucose</description>
          <units>Unitless</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="23"/>
                <count group_id="O2" value="19"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="410" lower_limit="118" upper_limit="1458"/>
                    <measurement group_id="O2" value="841" lower_limit="487" upper_limit="1491"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Pioglitazone</title>
          <description>pioglitazone tablet 45 mg once daily
pioglitazone: pioglitazone 45 mg daily: 23 subjects</description>
        </group>
        <group group_id="E2">
          <title>Placebo Pill</title>
          <description>placebo pill once daily (look-alike pill which contains no active ingredients)
placebo: one daily: 19 subjects</description>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="23"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="19"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Bacteremia with Streptococcus pneumoniae</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="23"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="19"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Surgical and medical procedures</title>
            <event_list>
              <event>
                <sub_title>Motor vehicle trauma</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="23"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>Right ankle trauma</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="23"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="19"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>4</frequency_threshold>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="23"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="19"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Lose consciousness</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>Fingers edema</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="23"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>Trauma</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="23"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="23"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="19"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="23"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="19"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Muscle cramps</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="23"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>Lipoma</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="23"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>Shoulder arthroplasty</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="23"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="19"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Urinary tract infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="19"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Menorrhagia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="19"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Ildiko Lingvay</name_or_title>
      <organization>UT Southwestern Medical Center</organization>
      <phone>214-648-2779</phone>
      <email>ildiko.lingvay@utsouthwestern.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

